Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia

類似資料

• Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
  著者:: DeAngelo, Daniel J., 等
  出版事項: (2020)
• Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
  著者:: Stock, Wendy, 等
  出版事項: (2020)
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
  著者:: Kantarjian, Hagop M., 等
  出版事項: (2019)
• Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
  著者:: DeAngelo, Daniel J., 等
  出版事項: (2017)
• Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
  著者:: Chen, Joseph, 等
  出版事項: (2020)